Latest Conference Articles

Second-Line Cabozantinib Improves PFS in Advanced RCC

Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.

Osimertinib Produces High Response Rate in EGFR T790M-Mutant NSCLC

The third-generation TKI osimertinib (AZD9291) showed a 71% objective response rate in patients with EGFR T790M-mutant non–small cell lung cancer following resistance to frontline anti-EGFR therapy.

Deep Sequencing Reveals Possible Primary Resistance Mechanism in EGFR-Mutant NSCLC

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

Cetuximab Improves Survival in EGFR-Positive Squamous NSCLC

The addition of cetuximab (Erbitux) to chemotherapy reduced the risk of death by 44% for patients with advanced squamous non–small cell lung cancer whose tumors test positive for EGFR gene amplification.

Survival Not Improved by Adjuvant Bevacizumab in NSCLC

The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

Survival Trends Higher With Necitumumab in EGFR FISH-Positive Squamous NSCLC

Survival for patients with metastatic squamous non–small cell lung cancer whose tumors were positive for EGFR copy number as determined by FISH analysis tended to be better when the EGFR antibody necitumumab was added to their conventional chemotherapy.

Potential Role Revealed for EGFR Inhibition Beyond Progression in NSCLC

Continued treatment with gefitinib beyond progression exhibited a trend toward better outcomes in patients with T790M-negative non­–small cell lung cancer.

Dr. Bauml on a New Platform to Enhance Lung Cancer Clinical Trial Enrollment

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses a novel IT platform designed to enhance lung cancer clinical trial enrollment.

Dr. Pelosof on the Increasing Incidence of Never Smokers in NSCLC

Lorraine Pelosof, MD, PhD, from The University of Texas Southwestern Medical Center, discusses a study looking at the incidence of never smokers diagnosed with non-small cell lung cancer (NSCLC).

Dr. Jänne on Biomarker Results From a Study of AZD9291

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Nivolumab/Ipilimumab Combination Active in Advanced NSCLC

A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced non–small cell lung cancer.

Nivolumab Survival Benefit Sustained in Squamous NSCLC

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Actionable Mutations Common in Young Lung Cancer Patients

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.

Bevacizumab Triplet Improves Survival in Mesothelioma

Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma.

Dr. Govindan on the Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Atezolizumab Plus Chemo Leads to High Response Rate in NSCLC

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

Dr. Vokes on Screening, Epidemiology, and Smoking in Lung Cancer

Everett E. Vokes, MD, chair, Department of Medicine, investigator of head and neck and lung cancer, University of Chicago, discusses a plenary session that covered prevention and screening at the 16th World Conference on Lung Cancer.

Overregulation May Delay Access to Life-Prolonging Medications, Increase Costs

Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.

Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

Second-Line Cetuximab Shows PFS Benefit in Wild-Type mCRC

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC

Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

Regorafenib Benefits Consistent in "Real World" mCRC Population

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

Improved OS, PFS Demonstrated by TAS-102, Regardless of KRAS Status

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

Adding Aprepitant Improves Control of Oxaliplatin-Related Nausea, Vomiting in CRC

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

Dr. Andrew Zhu on Ramucirumab for HCC

Andrew Zhu, MD, PhD, Associate Professor, Medicine, Harvard Medical School Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the REACH study, which looks at ramucirumab in advanced hepatocellular carcinoma.